Genmab A/S ADR (GMAB) Social Stream



Genmab A/S ADR (GMAB): $36.08

0.41 (-1.12%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

C

Add GMAB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#40 of 359

in industry

GENMAB A (GMAB) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering GENMAB A.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-11 6 $50 $37 $44.8 $37.36 19.91%
2021-11-15 7 $50 $37 $44.7 $37.36 19.65%
2022-01-18 8 $50 $37 $44.7 $37.36 19.65%
2022-01-31 8 $50 $37 $44.7 $37.36 19.65%
2022-02-28 8 $50 $37 $42.2 $37.36 12.96%
2022-04-07 8 $50 $33 $41.4 $37.36 10.81%
2022-04-11 9 $50 $33 $41.416 $37.36 10.86%
2022-04-21 9 $50 $30 $40.916 $37.36 9.52%
2022-05-02 10 $50 $30 $40.5 $37.36 8.4%
2022-05-12 10 $50 $30 $38.571 $37.36 3.24%
2022-05-13 10 $50 $30 $37.9 $37.36 1.45%
2022-06-05 10 $50 $29 $37.757 $37.36 1.06%
2022-07-20 11 $53 $29 $38.003 $37.36 1.72%
2022-08-13 11 $53 $29 $38.441 $37.36 2.89%
2022-08-15 11 $53 $31 $38.691 $37.36 3.56%
2022-08-25 11 $53 $31 $38.941 $37.36 4.23%
2022-10-19 11 $53 $31 $39.316 $37.36 5.24%
2022-11-10 12 $53 $31 $39.753 $37.36 6.41%
2022-11-14 12 $53 $33 $40.128 $37.36 7.41%
2022-12-03 13 $53 $33 $40.753 $37.36 9.08%
2023-01-03 13 $53 $33 $42.091 $37.36 12.66%
2023-01-26 13 $53 $33 $42.653 $37.36 14.17%
2023-02-22 13 $53 $34.73 $43.028 $37.36 15.17%
2023-02-23 13 $53 $34.73 $42.653 $37.36 14.17%
2023-02-26 13 $54 $34 $42.653 $37.36 14.17%
2023-03-27 13 $54 $33 $41.841 $37.36 11.99%
2023-04-20 13 $54 $33 $41.341 $37.36 10.66%
2023-05-11 12 $54 $34.73 $42.604 $37.36 14.04%
2023-05-16 11 $54 $33.001 $41.716 $37.36 11.66%
2023-05-22 11 $54 $33.001 $42.216 $37.36 13%
2023-05-25 12 $54 $33.001 $43.216 $37.36 15.67%
2023-06-26 11 $54 $33.001 $44.428 $37.36 18.92%
2023-08-03 12 $54 $33.001 $44.428 $37.36 18.92%
2023-08-15 12 $54 $33 $44.142 $37.36 18.15%
2023-08-24 13 $54 $33 $44.125 $37.36 18.11%
2023-09-12 14 $54 $33 $44.125 $37.36 18.11%

The Trend in the Analyst Price Target


Over the past 13 months, GMAB's average price target has gone up $5.18.

Over the past 49 weeks, GMAB's average upside potential has been 6.38%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-02-05 13 53 34.730 43.028 38.26 12.46%
2023-04-20 13 54 33.000 41.341 40.69 1.6%
2023-05-11 11 54 33.001 41.591 41.96 -0.88%
2023-05-22 11 54 33.001 42.216 42.37 -0.36%
2023-05-25 12 54 33.001 43.216 40.53 6.63%

GMAB Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2.48 5 0 7 1 1 14

The Trend in the Broker Recommendations


Over the past 18 months, GMAB's average broker recommendation rating improved by 0.25.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • To contextualize these metrics, consider that out of Pharmaceutical Products stocks, GENMAB A's upside potential (average analyst target price relative to current price) is higher than 638.78% of them.
  • GMAB has a greater average analyst price target than 1063.22% of stocks in the large market cap category.
  • To contextualize these metrics, consider that out of Pharmaceutical Products stocks, GENMAB A's number of analysts covering the stock is higher than 3271.28% of them.
  • To contextualize these metrics, consider that out of Pharmaceutical Products stocks, GENMAB A's variance in analysts' estimates is lower than -1299.08% of them.

In the Pharmaceutical Products industry, ELAN, APLS, and ZLAB are the three stocks most similar to GENMAB A regarding the price target and analyst recommendation information presented here.

Make investment decisions regarding GMAB using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!